Cognition Therapeutics, Inc. Stock-Based Compensation
Cognition Therapeutics, Inc. (CGTX) reported Stock-Based Compensation of $649.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-07
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $319.00K, a 48.63% decline year-over-year.
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $330.00K, a 43.69% decline year-over-year.
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $358.00K, a 32.96% decline year-over-year.
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $522.00K, a 41.74% decline year-over-year.
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $2.09M, a 44.32% decline from fiscal 2024.
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $3.75M, a 13.92% decline from fiscal 2023.
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $4.35M, a 21.89% increase from fiscal 2022.
- Cognition Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $3.57M, a 31.08% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $649.00K 10-Q · filed 2026-08-07 | $1.01M derived: sum of 3 quarters · filed 2026-08-07 | $1.53M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $330.00K 10-Q · filed 2026-05-08 | $688.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.21M derived: sum of 3 quarters · filed 2026-05-08 | $1.83M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $880.00K derived: sum of 2 quarters · filed 2026-03-26 | $1.50M derived: sum of 3 quarters · filed 2026-08-07 | $2.09M 10-K · filed 2026-03-26 |
| 2025-09-30 | $522.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.14M derived: sum of 2 quarters · filed 2026-08-07 | $1.73M 10-Q · filed 2025-11-06 | $2.26M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $621.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.21M 10-Q · filed 2026-08-07 | $1.74M derived: sum of 3 quarters · filed 2026-08-07 | $2.64M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $586.00K 10-Q · filed 2026-05-08 | $1.12M derived: sum of 2 quarters · filed 2026-05-08 | $2.02M derived: sum of 3 quarters · filed 2026-05-08 | $3.16M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $534.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.43M derived: sum of 2 quarters · filed 2026-03-26 | $2.58M derived: sum of 3 quarters · filed 2026-03-26 | $3.75M 10-K · filed 2026-03-26 |
| 2024-09-30 | $896.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.04M derived: sum of 2 quarters · filed 2025-11-06 | $3.21M 10-Q · filed 2025-11-06 | $4.29M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.32M 10-Q · filed 2025-08-07 | $3.39M derived: sum of 3 quarters · filed 2025-08-07 | $4.46M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-07 | $2.24M derived: sum of 2 quarters · filed 2025-05-07 | $3.31M derived: sum of 3 quarters · filed 2025-05-07 | $4.34M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.14M derived: sum of 2 quarters · filed 2025-03-20 | $3.17M derived: sum of 3 quarters · filed 2025-03-20 | $4.35M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.10M derived: sum of 2 quarters · filed 2024-11-13 | $3.28M 10-Q · filed 2024-11-13 | $4.18M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.21M 10-Q · filed 2024-08-08 | $3.11M derived: sum of 3 quarters · filed 2024-08-08 | $3.89M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.19M 10-Q · filed 2024-05-07 | $2.09M derived: sum of 2 quarters · filed 2024-05-07 | $2.87M derived: sum of 3 quarters · filed 2024-05-07 | $3.76M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $902.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $1.68M derived: sum of 2 quarters · filed 2024-03-26 | $2.57M derived: sum of 3 quarters · filed 2024-03-26 | $3.57M 10-K · filed 2024-03-26 |
| 2022-09-30 | $777.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.67M derived: sum of 2 quarters · filed 2023-11-02 | $2.67M 10-Q · filed 2023-11-02 | $7.59M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $892.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.89M 10-Q · filed 2023-08-08 | $6.81M derived: sum of 3 quarters · filed 2023-08-08 | $6.88M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.00M 10-Q · filed 2023-05-04 | $5.92M derived: sum of 2 quarters · filed 2023-05-04 | $5.99M derived: sum of 3 quarters · filed 2023-05-04 | $6.09M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $4.99M derived: sum of 2 quarters · filed 2023-03-23 | $5.08M derived: sum of 3 quarters · filed 2023-03-23 | $5.18M 10-K · filed 2023-03-23 |
| 2021-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $166.00K derived: sum of 2 quarters · filed 2022-11-14 | $264.00K 10-Q · filed 2022-11-14 | $397.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $192.00K 10-Q · filed 2022-08-09 | $325.00K derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $98.00K 10-Q · filed 2022-05-11 | $231.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $475.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $342.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |